Bharathi Raja Rajaganapathy1, Joseph J Janicki1, Peter Levanovich1, Pradeep Tyagi1, Jason Hafron1, Michael B Chancellor2, Sarah Krueger1, Brian Marples1. 1. Departments of Urology and Radiation Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan; Lipella Pharmaceuticals, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Departments of Urology and Radiation Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan; Lipella Pharmaceuticals, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: chancellormb@gmail.com.
Abstract
PURPOSE: We primarily determined whether the small animal radiation research platform could create a rat radiation cystitis model via targeted bladder irradiation (phase I). The response to treating early phase radiation cystitis in rats with transurethral catheter instillation of liposomal tacrolimus was also examined (phase II). MATERIALS AND METHODS: In phase I 16 adult female Sprague Dawley® rats were used. Metabolic urination patterns were analyzed before and after exposure to 20, 30 or 40 Gy radiation. In phase II irradiated rats were randomly assigned to receive a single instillation of saline or liposomal tacrolimus. RESULTS: The 40 Gy radiation dose induced statistically significant reductions in the intermicturition interval compared to the lower radiation doses. By approximately 20 minutes 40 Gy radiation caused a significant decrease in the mean intermicturition interval (p < 0.0001). Histological analysis revealed degenerative epithelial changes and urothelial swelling with evidence of pseudocarcinomatous epithelial hyperplasia. Therefore, 40 Gy were chosen for the phase II efficacy study. There was no measurable change in total voided urine volume after irradiation, or after liposomal tacrolimus or saline instillation. Liposomal tacrolimus significantly increased the post-irradiation intermicturition interval by approximately 30 minutes back to baseline (p < 0.001). CONCLUSIONS: The radiation cystitis rat model showed a dose dependent decrease in the intermicturition interval without inducing short-term skin or gastrointestinal damage. This study demonstrates that liposomal tacrolimus may be a promising new intravesical therapy for the rare, serious condition of radiation cystitis.
PURPOSE: We primarily determined whether the small animal radiation research platform could create a ratradiation cystitis model via targeted bladder irradiation (phase I). The response to treating early phase radiation cystitis in rats with transurethral catheter instillation of liposomal tacrolimus was also examined (phase II). MATERIALS AND METHODS: In phase I 16 adult female Sprague Dawley® rats were used. Metabolic urination patterns were analyzed before and after exposure to 20, 30 or 40 Gy radiation. In phase II irradiated rats were randomly assigned to receive a single instillation of saline or liposomal tacrolimus. RESULTS: The 40 Gy radiation dose induced statistically significant reductions in the intermicturition interval compared to the lower radiation doses. By approximately 20 minutes 40 Gy radiation caused a significant decrease in the mean intermicturition interval (p < 0.0001). Histological analysis revealed degenerative epithelial changes and urothelial swelling with evidence of pseudocarcinomatous epithelial hyperplasia. Therefore, 40 Gy were chosen for the phase II efficacy study. There was no measurable change in total voided urine volume after irradiation, or after liposomal tacrolimus or saline instillation. Liposomal tacrolimus significantly increased the post-irradiation intermicturition interval by approximately 30 minutes back to baseline (p < 0.001). CONCLUSIONS: The radiation cystitisrat model showed a dose dependent decrease in the intermicturition interval without inducing short-term skin or gastrointestinal damage. This study demonstrates that liposomal tacrolimus may be a promising new intravesical therapy for the rare, serious condition of radiation cystitis.
Authors: Joshua T Dilworth; Sarah A Krueger; George D Wilson; Brian Marples Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-01 Impact factor: 7.038
Authors: John Wong; Elwood Armour; Peter Kazanzides; Iulian Iordachita; Erik Tryggestad; Hua Deng; Mohammad Matinfar; Christopher Kennedy; Zejian Liu; Timothy Chan; Owen Gray; Frank Verhaegen; Todd McNutt; Eric Ford; Theodore L DeWeese Journal: Int J Radiat Oncol Biol Phys Date: 2008-08-01 Impact factor: 7.038
Authors: J Curtis Nickel; Michael A Gorin; Alan W Partin; Dean Assimos; Michael Brawer; Heinz Nicolai; Michael B Chancellor; Áine Goggins; Stacy Loeb; Ellen Shapiro Journal: Rev Urol Date: 2015
Authors: Bernadette M M Zwaans; Marissa Grobbel; Alexander L Carabulea; Laura E Lamb; Sara Roccabianca Journal: Acta Biomater Date: 2022-03-14 Impact factor: 10.633
Authors: Chirag N Dave; Fahad Chaus; Michael B Chancellor; Michelle Lajness; Kenneth M Peters Journal: Int Urol Nephrol Date: 2015-09-07 Impact factor: 2.370
Authors: Bernadette M M Zwaans; Sarah Krueger; Sarah N Bartolone; Michael B Chancellor; Brian Marples; Laura E Lamb Journal: Adv Radiat Oncol Date: 2016-08-01
Authors: Joseph J Janicki; Michael B Chancellor; Jonathan Kaufman; Michele A Gruber; David D Chancellor Journal: Toxins (Basel) Date: 2016-03-18 Impact factor: 4.546
Authors: Stefania Zuppone; Andrea Bresolin; Antonello E Spinelli; Giuseppe Fallara; Roberta Lucianò; Federico Scarfò; Fabio Benigni; Nadia Di Muzio; Claudio Fiorino; Alberto Briganti; Andrea Salonia; Francesco Montorsi; Riccardo Vago; Cesare Cozzarini Journal: Front Oncol Date: 2020-10-22 Impact factor: 6.244